Key Highlights

  • Actinogen Medical Limited (ASX:ACW) reports that Xanamem was numerically but not statistically superior to placebo on the primary endpoint in the overall XanaMIA population.
  • Older participants showed what the company describes as clinically significant and sustained disease slowing of 30%, leading to a new Patent filing.
  • Xanamem was safe and well tolerated over the 36-week treatment period, according to the company.
  • The company holds $18.9 million in cash with no debt, and says it is suspending future Phase 3 expenditure to conserve funds.

Actinogen Medical Limited (ASX:ACW) has released topline results from its pivotal, placebo-controlled XanaMIA trial of oral emestedastat, marketed as Xanamem, in Alzheimer’s disease. The announcement, dated 19 November 2026, covers 247 patients with mild to moderate disease and elevated pTau181 levels, treated for 36 weeks. The overall population did not reach statistical significance on the primary endpoint, while the company highlighted results in older participants.

Primary Endpoint and Overall Population

In the overall population, Xanamem was numerically, but not statistically, superior to placebo for the primary endpoint of delayed disease progression, measured by the Clinical Dementia Rating Scale Sum of Boxes. The company also disclosed that an interim analysis in January 2026 had shown a statistically significant benefit of 0.58 points at Week 24 among 88 participants, which was not fully sustained in the final analysis of 247 participants.

The company says the safety profile was consistent with its earlier studies, with Xanamem safe and well tolerated over the treatment period.

Older Participants and the Open Label Extension

Actinogen reports clinically significant and sustained disease slowing of 30% in older participants, which has prompted a new patent filing covering treatment of older, more advanced patients. The company says these patients represent more than 70% of Alzheimer’s patients and are underserved by existing therapies.

In the open label extension, the first 29 participants to reach 24 weeks of active therapy showed no mean progression on the CDR-SB measure. The OLE will continue, with the next data milestone expected in the first quarter of CY2027 when about 100 participants have reached 24 weeks.

Funding, Cost Actions and Interpretation

The company had $18.9 million in cash and no Debt at the time of the announcement. It has suspended future Phase 3 expenditure, focused spending on the OLE trial and is pursuing Business development. Management says the Balance Sheet provides a runway into CY2028 and the optionality to evaluate the XanaMIA data with potential co-development partners.

The older-participant result is a subgroup finding, and the company’s description of it as clinically significant is its own assessment. The overall primary endpoint was not statistically significant.

Looking Ahead

The next steps are the analysis of the XanaMIA trial with potential partners and the OLE data milestone in early 2027. Whether the older-patient finding leads to a development path will depend on those discussions and on the continuing OLE results.